Could CRISPR End Sickle Cell Anemia?

Emily Mullin, MIT Technology Review, 23 August 2017,

Sickle cell anemia affects approximately 100,000 individuals in the US – mostly of African or Hispanic descent – and results in a significantly reduced life expectancy.  While the cause of sickle cell anemia has been known for 100 years, the genetic nature of the disease has made it difficult to treat.  With the development of the CRISPR/Cas gene editing system, sickle cell patients are hopeful that a cure may be possible.  This article discusses this possibility with sickle cell patients as well as examining what a treatment may look like.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply